| Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective … W De Roock, B Claes, D Bernasconi, J De Schutter, B Biesmans, ... The lancet oncology 11 (8), 753-762, 2010 | 2564 | 2010 |
| Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer E Razis, M Bobos, V Kotoula, AG Eleftheraki, HP Kalofonos, K Pavlakis, ... Breast cancer research and treatment 128, 447-456, 2011 | 225 | 2011 |
| Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer KS Purrington, S Slager, D Eccles, D Yannoukakos, PA Fasching, P Miron, ... Carcinogenesis 35 (5), 1012-1019, 2014 | 209 | 2014 |
| Evaluation of PD-L1 expression and associated tumor-infiltrating lymphocytes in laryngeal squamous cell carcinoma M Vassilakopoulou, M Avgeris, V Velcheti, V Kotoula, T Rampias, ... Clinical Cancer Research 22 (3), 704-713, 2016 | 207 | 2016 |
| Antitumor Effects of the Proteasome Inhibitor Bortezomib in Medullary and Anaplastic Thyroid Carcinoma Cells in Vitro CS Mitsiades, D McMillin, V Kotoula, V Poulaki, C McMullan, J Negri, ... The Journal of Clinical Endocrinology & Metabolism 91 (10), 4013-4021, 2006 | 158 | 2006 |
| Fas/Fas ligand up-regulation and Bcl-2 down-regulation may be significant in the pathogenesis of Hashimoto’s thyroiditis N Mitsiades, V Poulaki, V Kotoula, G Mastorakos, S Tseleni-Balafouta, ... The Journal of Clinical Endocrinology & Metabolism 83 (6), 2199-2203, 1998 | 155 | 1998 |
| Regulation of vascular endothelial growth factor expression by insulin-like growth factor I in thyroid carcinomas V Poulaki, CS Mitsiades, C McMullan, D Sykoutri, G Fanourakis, ... The Journal of Clinical Endocrinology & Metabolism 88 (11), 5392-5398, 2003 | 146 | 2003 |
| Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes G Pentheroudakis, V Kotoula, W De Roock, G Kouvatseas, P Papakostas, ... BMC cancer 13, 1-12, 2013 | 143 | 2013 |
| Fas ligand is present in tumors of the Ewing's sarcoma family and is cleaved into a soluble form by a metalloproteinase N Mitsiades, V Poulaki, V Kotoula, A Leone, M Tsokos The American journal of pathology 153 (6), 1947-1956, 1998 | 116 | 1998 |
| Tumor PIK3CA genotype and prognosis in early-stage breast cancer: a pooled analysis of individual patient data D Zardavas, L Te Marvelde, RL Milne, D Fumagalli, G Fountzilas, ... Journal of Clinical Oncology 36 (10), 981-990, 2018 | 112 | 2018 |
| Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells V Poulaki, CS Mitsiades, V Kotoula, S Tseleni-Balafouta, A Ashkenazi, ... The American journal of pathology 161 (2), 643-654, 2002 | 110 | 2002 |
| Volumetric and MGMT parameters in glioblastoma patients: survival analysis G Iliadis, V Kotoula, A Chatzisotiriou, D Televantou, AG Eleftheraki, ... BMC cancer 12, 1-13, 2012 | 100 | 2012 |
| Targeted KRAS mutation assessment on patient tumor histologic material in real time diagnostics V Kotoula, E Charalambous, B Biesmans, A Malousi, E Vrettou, ... PloS one 4 (11), e7746, 2009 | 97 | 2009 |
| Fas ligand expression in thyroid carcinomas: a potential mechanism of immune evasion N Mitsiades, V Poulaki, G Mastorakos, S Tseleni-Balafouta, V Kotoula, ... The Journal of Clinical Endocrinology & Metabolism 84 (8), 2924-2932, 1999 | 90 | 1999 |
| Revisiting OCT4 expression in peripheral blood mononuclear cells V Kotoula, SI Papamichos, AF Lambropoulos Stem cells 26 (1), 290-291, 2008 | 87 | 2008 |
| Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin … D Pectasides, V Karavasilis, G Papaxoinis, G Gourgioti, T Makatsoris, ... BMC cancer 15, 1-11, 2015 | 82 | 2015 |
| Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib MG Ooi, PJ Hayden, V Kotoula, DW McMillin, E Charalambous, ... Clinical Cancer Research 15 (23), 7153-7160, 2009 | 82 | 2009 |
| Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel G Fountzilas, U Dafni, M Bobos, A Batistatou, V Kotoula, H Trihia, ... PloS one 7 (6), e37946, 2012 | 81 | 2012 |
| Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis CS Mitsiades, V Kotoula, V Poulaki, E Sozopoulos, J Negri, ... The Journal of Clinical Endocrinology & Metabolism 91 (9), 3662-3666, 2006 | 78 | 2006 |
| Telomerase activity in precancerous hepatic nodules P Hytiroglou, V Kotoula, SN Thung, M Tsokos, MI Fiel, CS Papadimitriou Cancer: Interdisciplinary International Journal of the American Cancer …, 1998 | 76 | 1998 |
